AstraZeneca described a semi‑automated liquid chromatography–mass spectrometry (LC–MS) screening platform to streamline oligonucleotide analytical characterization across early discovery and CMC stages. The dual workflow aims to reduce reliance on bespoke laboratory tests, speed throughput and improve reproducibility when assessing hundreds to thousands of oligonucleotide candidates. The platform covers rapid screening and detailed characterization needs and is positioned to reduce attrition caused by analytical bottlenecks, potentially rescuing oligo candidates that previously failed due to assay limitations. The method targets the scale challenges created by the expanding oligonucleotide therapeutics market. Adopters noted the potential for harmonized, semi‑automated analytics to compress development timelines and improve the yield of viable clinical candidates from large discovery libraries.